<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02118337</url>
  </required_header>
  <id_info>
    <org_study_id>D6020C00001</org_study_id>
    <nct_id>NCT02118337</nct_id>
  </id_info>
  <brief_title>A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies</brief_title>
  <official_title>A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with
      Durvalumab versus Nivolumab Monotherapy in Subjects with Select Advanced Malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, Phase 1/2 study to evaluate the safety, tolerability, PK,
      immunogenicity, and antitumor activity of MEDI0680 in combination with durvalumab or
      nivolumab monotherapy in adult immunotherapy-na√Øve subjects with selected advanced
      malignancies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2014</start_date>
  <completion_date type="Anticipated">March 26, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 26, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Escalation: Number of subjects with adverse events</measure>
    <time_frame>From first dose of study drugs until 90 days after the last dose of study drugs</time_frame>
    <description>Assessed by number of subjects with AEs and SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Expansion: Antitumor activity</measure>
    <time_frame>From first dose of study drug through study completion</time_frame>
    <description>Determination of antitumor activity based on investigator assessed response using RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Escalation: Antitumor activity of MEDI0680 in combination with MEDI4736 in subjects with select advanced malignancies</measure>
    <time_frame>From first dose of study drugs through study completion</time_frame>
    <description>Determination of antitumor activity based on investigator assessed response using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion: Safety of MEDI0680 Monotherapy and in combination with MEDI4736</measure>
    <time_frame>From first dose through 90 days after last dose of study drugs</time_frame>
    <description>To be assessed by number of subjects with AEs and SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Expansion: Antitumor activity of MEDI0680 monotherapy and in combination with MEDI4736</measure>
    <time_frame>From the time of first dose through study completion</time_frame>
    <description>Determination of antitumor activity based on blinded independent central review assessed response using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Both Phases: Pharmacokinetics of MEDI0680 monotherapy and in combination with MEDI4736 and MEDI4736 in combination with MEDI0680</measure>
    <time_frame>From first dose until 12 months after the last dose</time_frame>
    <description>Pharmacokinetics as measured by drug concentration in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Both Phases: Immunogenicity of MEDI0680 and MEDI4736</measure>
    <time_frame>From first dose of study drugs until 12 months after last dose of study drugs</time_frame>
    <description>Immunogenicity as measured by presence of detectable ADAs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-L1 as a predictive biomarker</measure>
    <time_frame>From first dose of study drug through study completion</time_frame>
    <description>PD-L1 expression on the tumor membrane and tumor-infiltrating immune cells within the tumor microenvironment</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Select Advanced Malignancies</condition>
  <condition>Kidney Cancer</condition>
  <condition>Clear Cell Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>0.1 mg/kg MEDI0680 Q2W; 3 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0680 and Durvalumab in combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nivolumab monotherapy at the selected dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0680 and Durvalumab combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0680 and Durvalumab in combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.5 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0680 and Durvalumab in combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0680 and Durvalumab in combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0680 and Durvalumab in combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg/kg MEDI0680 Q2W; 750 mg durvalumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0680 and Durvalumab in combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI0680</intervention_name>
    <description>anti-PD-1</description>
    <arm_group_label>0.1 mg/kg MEDI0680 Q2W; 3 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>0.5 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>0.1 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>2.5 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>10 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>20 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>20 mg/kg MEDI0680 Q2W; 750 mg durvalumab Q2W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>anti-PD-L1</description>
    <arm_group_label>0.1 mg/kg MEDI0680 Q2W; 3 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>0.5 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>0.1 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>2.5 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>10 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
    <arm_group_label>20 mg/kg MEDI0680 Q2W; 10 mg/kg durvalumab Q2W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>anti PD-1</description>
    <arm_group_label>Nivolumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be 18 years or older

          -  Eastern Cooperative Oncology Group performance status of 0-1

          -  Adequate organ function

          -  At least 1 prior line of therapy

        Exclusion Criteria:

          -  Concurrent enrollment in another clinical study, unless in follow-up period or it is
             an observational study

          -  Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer
             treatment

          -  Prior treatment with immunotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Chow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Omid Hamid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Angeles Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jhanelle Gray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rachel Sanborn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamad Salkeni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mary Babb Randolph Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monika Joshi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State Hershey Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Alter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Theurer Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raid Aljumaily, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peggy Charles Stephenson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jason Chesney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Quevedo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Voss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johanna Bendell</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Henry</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola Univ. Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lionel Lewis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian Rini</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Van Veldhuizen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Menorah Medical Center tour</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>AstraZeneca Cancer Study Locator Service</last_name>
    <phone>1-877-400-4656</phone>
    <email>AstraZeneca@emergingmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>East Bentleigh</city>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankston</city>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gosford</city>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hobart</city>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Leonards</city>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seongnam-si</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Songpa-gu</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2014</study_first_submitted>
  <study_first_submitted_qc>April 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>select advanced malignancies,</keyword>
  <keyword>kidney cancer,</keyword>
  <keyword>clear cell renal cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

